Stock Track | Agios Pharmaceuticals Plunges on Disappointing Q3 Results, Earnings Miss

Stock Track10-31

Shares of Agios Pharmaceuticals Inc. (NASDAQ: AGIO) plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' estimates on both earnings and revenue.

The Cambridge, Massachusetts-based company reported earnings of $4.20 per share for the quarter, significantly missing the Zacks Consensus Estimate of $16.69 per share. Revenue for the quarter came in at $8.96 million, falling short of analysts' expectations of $9.46 million.

The earnings miss marked the fourth time in the last five quarters that Agios Pharmaceuticals has fallen short of Wall Street's projections. The company's stock has more than doubled since the beginning of the year, but the latest results have raised concerns about its ability to sustain the momentum.

While the company's management is expected to provide further insights during the earnings call, the sustainability of the stock's price movement will largely depend on future earnings expectations and the company's outlook. With a Zacks Rank of #3 (Hold), the stock is expected to perform in line with the market in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159094832?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159094832","market":"us","top_or_hot":-1,"title":"Stock Track | Agios Pharmaceuticals Plunges on Disappointing Q3 Results, Earnings Miss","media":"Stock Track","content":"<p>Shares of Agios Pharmaceuticals Inc. (NASDAQ: AGIO) plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' estimates on both earnings and revenue.</p>\n\n<p>The Cambridge, Massachusetts-based company reported earnings of $4.20 per share for the quarter, significantly missing the Zacks Consensus Estimate of $16.69 per share. Revenue for the quarter came in at $8.96 million, falling short of analysts' expectations of $9.46 million.</p>\n\n<p>The earnings miss marked the fourth time in the last five quarters that Agios Pharmaceuticals has fallen short of Wall Street's projections. The company's stock has more than doubled since the beginning of the year, but the latest results have raised concerns about its ability to sustain the momentum.</p>\n\n<p>While the company's management is expected to provide further insights during the earnings call, the sustainability of the stock's price movement will largely depend on future earnings expectations and the company's outlook. With a Zacks Rank of #3 (Hold), the stock is expected to perform in line with the market in the near future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Agios Pharmaceuticals Plunges on Disappointing Q3 Results, Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Agios Pharmaceuticals Plunges on Disappointing Q3 Results, Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-31 21:46 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Agios Pharmaceuticals Inc. (NASDAQ: AGIO) plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1159094832","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159094832","pubTimestamp":1730382414,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Agios Pharmaceuticals Inc.  plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' estimates on both earnings and revenue.The Cambridge, Massachusetts-based company reported earnings of $4.20 per share for the quarter, significantly missing the Zacks Consensus Estimate of $16.69 per share. Revenue for the quarter came in at $8.96 million, falling short of analysts' expectations of $9.46 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"股票追踪Agios Pharmaceuticals因第三季度业绩令人失望、盈利未达预期而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1},"content_text":"Shares of Agios Pharmaceuticals Inc. (NASDAQ: AGIO) plummeted by 5.94% on Wednesday after the biopharmaceutical company reported disappointing third-quarter 2024 financial results, missing analysts' estimates on both earnings and revenue.\nThe Cambridge, Massachusetts-based company reported earnings of $4.20 per share for the quarter, significantly missing the Zacks Consensus Estimate of $16.69 per share. Revenue for the quarter came in at $8.96 million, falling short of analysts' expectations of $9.46 million.\nThe earnings miss marked the fourth time in the last five quarters that Agios Pharmaceuticals has fallen short of Wall Street's projections. The company's stock has more than doubled since the beginning of the year, but the latest results have raised concerns about its ability to sustain the momentum.\nWhile the company's management is expected to provide further insights during the earnings call, the sustainability of the stock's price movement will largely depend on future earnings expectations and the company's outlook. With a Zacks Rank of #3 (Hold), the stock is expected to perform in line with the market in the near future.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159094832"}